Full-Time

Senior Director

Migraine

Posted on 12/4/2025

Deadline 12/9/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$204.7k - $341.1k/yr

+ Bonus (target 22.5%) + Long-term incentive program

Pennsylvania, USA + 4 more

More locations: Florida, USA | Waterbury, CT, USA | New York, NY, USA | Massachusetts, USA

Remote

Preference to be within 50 miles of a Pfizer site; remote candidates considered; relocation assistance available for those >50 miles.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Science
Machine Learning
Requirements
  • Advanced degree, including PhD in Epidemiology, population health, outcomes research, or a related discipline and 7+ years of relevant experience in the pharmaceutical, academic and/or medical environments (at least 3 of which need to be at a pharmaceutical company or partnering with pharmaceutical companies); or MPH or another relevant Masters degree, and 10+ years of experience with similar requirements as previously stated.
  • Experience operating within large cross-functional matrices and collaborating with multiple partners.
  • Strong technical expertise, analytic ability, creative problem-solving, and communication skills.
  • Experience directing analyses of real-world data.
  • Proven hands-on experience executing non-interventional studies (NIS) from protocol design to delivery of results and clinical study report.
  • Knowledgeable of the external regulatory environment for RWE and maintains awareness of scientific developments in epidemiology, medicine, and technology (e.g., artificial intelligence).
Responsibilities
  • Design, lead and execute RWE/Epi studies as part of cross-functional IEPs
  • Provide subject matter expertise (SME) and thought leadership to advance Pfizer’s use of RWE/Epi to develop high value medicines.
  • Partner with TA RWE/Epi lead and MEG TA Leads to ensure strategic input is being provided to IEPs through Global Medical Affairs Teams
  • Work collaboratively to establish & operationalize processes & systems to deliver RWE/Epi studies and other deliverables to execute on IEP plans
  • Stakeholder management: build coalitions & develop strong partnerships across disciplines & geographies to optimize RWE/Epi team’s performance / contribution
  • Provide critical assessments to inform asset-specific development strategy & cross-functional decision-making and review of epidemiological data and literature, when needed.
  • Prepare study reports, and present /publish results of epidemiological studies at scientific conferences and in peer-reviewed journals
  • Participate in RWE/Epi peer review of study protocols and study reports
  • Provide SME on US RWD available at Pfizer, including major differences between databases and which types of research questions each can answer
  • Deep expertise in common types of commercially available RWD in the US, including closed claims, open claims, structured EHR, unstructured EHR, linked claims + EHR, hospital chargemaster, surveys, telehealth, and registries
  • Ability to rapidly assess feasibility of answering research questions with available RWD
  • Manage feasibility analyses for development of study concepts
  • Develop study concepts, present to GMAT and other appropriate governance, and address concerns until concepts are approved
  • Develop study protocols for approved concepts, present to GMAT, address concerns, and ensure they are conducted according to governing SOPs
  • Supervise and mentor more junior team members
  • Act as SME for observational and NIS study design in accordance with generally accepted scientific principles and regulatory guidance
Desired Qualifications
  • Ability to develop and implement strategic plans and business objectives.
  • Strong problem-solving skills and the ability to influence senior leadership.
  • Prior experience in developing RWE for neurological conditions (e.g., pain, headache, migraine) where key patient-reported outcomes that may not be readily available in RWD
  • Candidate demonstrates breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.
  • Work Location Assignment: Preference for candidates to be within 50 miles of a Pfizer site, however, will consider remote candidates.
  • Relocation Support Possible for candidates more than 50 miles from a Pfizer site.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
  • VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.

What critics are saying

  • Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
  • Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
  • Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.

What makes Pfizer unique

  • Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
  • Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
  • Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE